issues
July/August 2008
Download PDFTABLE OF CONTENTS
Living the Dream!
Derrek G. Hennecke, MBA, continues with part 6 of his 7-part series chronicling the challenges, issues, and more importantly, the opportunities he faced throughout his successful Management Buy-Out.
Mucoadhesive Bilayered Buccal Tablets of Propranolol Hydrochloride: Pharmacodynamic Study in Rabbits
V.M. Patel, MPharm; R.J. Patel, MPharm; J.K. Patel, PhD; and M.M. Patel, PhD; study mucoadhesive bilayered buccal tablets of propranolol hydrochloride using a combination of sodium alginate and Carbopol-934 with ethyl cellulose as an impermeable backing layer.
30th Anniversary of the Franz Cell Finite Dose Model: The Crystal Ball of Topical Drug Development
Sam Raney, PhD; Paul Lehman, MSc; and Thomas Franz, MD; commemorate the 30th anniversary of the Franz Cell and the in vitro Finite Dose Model, which revolutionized strategic drug development for topical and transdermal formulations.
Transdermal Delivery Becoming More Active
Contributor Cindy H. Dubin speaks with some of the industry’s leading companies to find out the hot trends in active and passive transdermal technology, the systems these firms are developing, and where the future of this exciting sector is headed.
Gastro-Retentive Drug Delivery: A Technical Note
Atishkumar S. Mundada, Natasha V. Bhola, and J.G. Avari, PhD, highlight the various criteria required by a drug to be suitable for gastric retention, the process of gastric emptying, and different approaches (along with their advantages and shortcomings) to formulate GRDDS.
New Controlled Release Technologies Broaden Opportunities for Ophthalmic Therapies
Daniel J. Haders II, PhD, believes substantial market opportunities exist for companies in the ophthalmic pharmaceutical sector that pursue novel molecules, innovative drug delivery systems, or both.
Controlled Release of Dipyridamole From Floating Matrices Prepared Using Glyceryl Behenate
V.F. Patel, MPharm, and N.M. Patel, PhD, study gylceryl behenate as a matrix-forming agent to control the release of poorly water-soluble drugs, such as dipyridamole.
BioDelivery Sciences International: Improving Existing Therapeutics Using Novel Technologies
Drug Delivery Executive: Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences, discusses the company’s proprietary technologies, product pipeline, and strategic corporate vision.
Advancing Discovery & Development of Monoclonal Antibody Therapeutics
Nicholas C. Nicolaides, PhD, believes the rapidly growing monoclonal therapeutic antibody market has created significant value and demand for antibody development technologies, such as Morphotek’s unique platform to generate and optimize monoclonal antibodies and specifically target a disease-associated antigen.
Outsourcing Trends in Specialty Pharma – Challenges & Future Outlook
Research Analyst Barath Shankar indicates that despite significant growth within the global CRO market, the pharma industry has yet to catch up with other technology-based industries that have “mastered” outsourcing and have moved from using it as just a cost advantage to leveraging several key benefits.
Silo-Marketing is a Waste
Malcolm A. Teasdale says the best way to bring in new customers and drive your bottom line is to mix it up, develop a strong message derived from fact-based research, and then use it to engage your potential customers with all the media and channels they tune into.
Virionyx: Partnering With the Immune System to Fight a Range of Diseases
Executive Summary: Mr. Simon Wilkinson, CEO of Virionyx, tells about the challenges he faces in getting his company’s programs to the point at which they are ready for partnering in international markets.
DEPARTMENTS
Market News & Trends
Attorney Review
An Update on Intellectual Property News
Technology Showcase
Facts & Figures
External Delivery
Take Me to Your Leader
COVER
FEATURES
